• Explore /
  • Poster
  • / Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).

Abstract Poster

Authors

null

In Hae Park

Division of Hemato-Oncology, Department of Internal Medicine, Korea University College of Medicine, Guro Hospital, Seoul, South Korea

In Hae Park , Gun Min Kim , Jee Hyun Kim , Hanjo Kim , Kyong Hwa Park , Yeon Hee Park , Sun Kyung Baek , Sung Hoon Sim , Hee Kyung Ahn , Gyeong-Won Lee , Kyoung Eun Lee , Ji Eun Lee , Seungtaek Lim , Kyung Hae Jung , Seock-Ah Im

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT03756298

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS597)

DOI

10.1200/JCO.2020.38.15_suppl.TPS597

Abstract #

TPS597

Poster Bd #

89

Abstract Disclosures

Similar Posters

First Author: Zhi Peng

First Author: Heather L. McArthur

First Author: Min Yan

First Author: Gabriel Rinnerthaler